MRK
Merck & Co., Inc.
Drug Manufacturers - General · Healthcare · United States
146.33
close · 2026-10-29
value
40
cheaper than peers40
quality
33
stronger fundamentals33
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 15.85× | 62 |
| EV to EBITDA | 13.66× | 58 |
| price to sales | 5.42× | 41 |
| price to book | 8.61× | 20 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 7.0% | 77 |
| operating margin | -0.2% | 43 |
| revenue growth | 5.1% | 37 |
| debt to equity | 128.4% | 19 |
4 of 4 measures available
Facts
| market cap | $361B |
| free cash flow | $15.17B |
| employees | 73,000 |
| first trade | 1962-01-02 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 7.28 | 6.74 | 0.14 | 5.71 |
| free cash flow | $12.36B | $18.10B | $9.14B | $14.71B |
| net income | $18.25B | $17.12B | $365.0M | $14.52B |
| revenue | $65.01B | $64.17B | $60.12B | $59.28B |
| unusual items | -$844.0M | -$522.0M | -$629.0M | -$1.99B |